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Summary
 
Autoimmune diabetes is caused by the CD4
 
1
 
, T helper 1 (Th1) cell-mediated apoptosis of in-
sulin-producing 
 
b
 
 cells. We have previously shown that Th2 T cells bearing the same T cell
receptor (TCR) as the diabetogenic Th1 T cells invade islets in neonatal nonobese diabetic
(NOD) mice but fail to cause disease. Moreover, when mixed in excess and cotransferred with
Th1 T cells, Th2 T cells could not protect NOD neonates from Th1-mediated diabetes. We
have now found, to our great surprise, the same Th2 T cells that produced a harmless insulitis
in neonatal NOD mice produced intense and generalized pancreatitis and insulitis associated
with islet cell necrosis, abscess formation, and subsequent diabetes when transferred into immu-
nocompromised NOD.
 
scid
 
 mice. These lesions resembled allergic inflamation and contained a
large eosinophilic infiltrate. Moreover, the Th2-mediated destruction of islet cells was medi-
ated by local interleukin-10 (IL-10) production but not by IL-4. These findings indicate that
under certain conditions Th2 T cells may not produce a benign or protective insulitis but
rather acute pathology and disease. Additionally, these results lead us to question the feasibility
of Th2-based therapy in type I diabetes, especially in immunosuppressed recipients of islet cell
transplants.
 
I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 is caused by
the autoimmune destruction of insulin-producing 
 
b
 
 cells
in the islets of Langerhans of the pancreas (1, 2). The leuko-
cytic infiltration, termed insulitis, is a heterogeneous mixture
of CD4
 
1
 
 and CD8
 
1
 
 T lymphocytes, B lymphocytes, mac-
rophage and dendritic cells (3). In general, T lymphocytes,
play the most pivotal role in initiating the disease process
(4–7). Recently, we demonstrated that islet cell antigen-
responsive CD4
 
1
 
 T cells alone are sufficient for the sponta-
neous development and transfer of diabetes in NOD.
 
scid
 
mice (8).
CD4
 
1
 
 T cells can be differentiated into at least two ma-
jor subsets, Th1 cells that secrete IFN-
 
g
 
 and Th2 cells that
produce IL-4 and IL-10. Th1 cells are critically involved in
the generation of effective cellular immunity (9), whereas
Th2 T cells are instrumental in the generation of humoral
and mucosal immunity and allergy, including the activation
of eosinophils and mast cells and the production of IgE (9).
A number of studies have now correlated diabetes with
Th1 phenotype development (10–12). On the other hand,
Th2 T cells were shown to be relatively innocuous (12–
15). Some have even speculated that Th2 T cells in fact,
may be protective (16–19), although direct evidence in
support of Th2-mediated protection is lacking.
We have previously reported that the ability of CD4
 
1
 
T cells to transfer diabetes to naïve recipients resided not
with the antigen specificity recognized by the TCR, per se,
but with the phenotypic nature of the T cell response (12).
Strongly polarized Th1 T cells transferred disease into NOD
neonatal mice, while Th2 T cells did not, despite being ac-
tivated and bearing the same TCR as the diabetogenic Th1
T cell population. Moreover, upon cotransfer, Th2 T cells
could not ameliorate the Th1-induced diabetes, even when
Th2 cells were cotransferred in 
 
z
 
10-fold excess (12).
However, we wondered if we transferred Th2 cells be-
fore transfer of Th1 cells, we might amplify the protective
influence of Th2 cells, and thereby control the subsequent
Th1 T cell response. In this study, we attempt to evaluate
directly this hypothesis by producing Th1 and Th2 T cells
from the islet-reactive BDC2.5 TCR transgenic NOD mouse
(20), and then transfer sequentially Th2 and then Th1 T cells
into NOD recipients mice.
Much to our surprise, we found that Th2 T cells exerted
markedly differing effects on NOD recipients depending
on the immune status of the recipient mouse. Here, we re-
port that while Th1-polarized T cells can transfer disease in
neonatal NOD mice, something Th2-polarized T cell fail
 
1
 
Abbreviations used in this paper: 
 
AEC, aminoethylcarbazole; DAB, diami-
nobenzidine; IDDM, insulin-dependent diabetes mellitus; PNA, periph-
eral node addressin.
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to do, both Th1- and Th2-polarized T cells can transfer
disease in NOD.
 
scid
 
 mice and other immune-compromised
recipients. The Th2-mediated diabetes in NOD.
 
scid
 
 recipi-
ents exhibited a longer prediabetic phase and a lowered over-
all incidence. Moreover, the diabetic lesion created by Th2
cells was unique and quite unlike the lesion found in spon-
taneously diabetic BDC2.5 mice or Th1 T cell–induced di-
abetes in either neonates or NOD.
 
scid
 
 mice. That Th2 cells
caused a distinct but important disease in immune-compro-
mised recipients has significant implications with regard to
the potential use of Th2 cells as a therapeutic agent.
 
Materials and Methods
 
Mice.
 
BDC2.5 TCR transgenic mice were described previ-
ously (20). Mice used in these experiments were housed under
specific pathogen-free conditions and were backcrossed to NOD/lt
for 
 
.
 
20 generations. The NOD.
 
scid
 
 mice were bred under
pathogen-free conditions at Washington University from an orig-
inal breeding stock provided by Dr. E. Leiter of the Jackson Lab-
oratories.
 
Flow Cytometry.
 
Flow cytometry was performed on either a
Becton Dickinson FACScan
 
Ò
 
 or FACSVantage
 
Ò
 
 flow cytometer.
We purchased anti-CD4–PE mAb (Caltag Laboratory, South San
Francisco, CA). mAb to the 
 
b
 
 chain of the transgenic TCR,
KT4-10 (21), was purified from ascites and conjugated with
FITC. List mode data was collected on 1 
 
3
 
 10
 
5
 
 cells and reana-
lyzed using WinMDI (version 2.1.4) software written by J. Trot-
ter (http://facs.scripps.edu).
 
Diabetes.
 
Diabetes was assessed by measurement of venous
blood using a Bayer Glucometer Elite one-step blood glucose meter.
Animals were considered diabetic after two consecutive measure-
ments 
 
>
 
250 mg/dl (13.75 mM). Onset of diabetes was dated
from the first consecutive reading. In most instances, sustained
hyperglycemia of 
 
.
 
500 mg/dl was observed, and animals were
killed to avoid prolonged discomfort.
 
Immunohistochemistry.
 
Mice were killed by cervical dislocation
or CO
 
2
 
 asphyxiation. The entire pancreata were removed, fixed
either in 10% neutral-buffered formalin at 4
 
8
 
C for at least 20 h
but not more than 26 h, embedded in paraffin, and sections (2 
 
m
 
m),
collected on poly 
 
l
 
-lysine coated slides (VWR Scientific Prod-
ucts, Corp., Philadelphia, PA). Alternatively, pancreata were snap
frozen in OCT compound (Tissue-tek) for cryosectioning. 5-
 
m
 
m
cryosections were obtained, air dried, and stored at 
 
2
 
20
 
8
 
C until
used. Formalin-fixed sections were deparaffinized in xylene and
alcohol, and stained with hematoxylin and eosin for general mor-
phology.
Sections were stained using the TUNEL procedure (modified
from reference 22) to detect apoptosis as described previously (8)
and counterstained with hematoxylin. In brief, sections were di-
gested with Proteinase K (20 
 
m
 
g/ml for 15 min), endogenous
peroxidase was blocked in hydrogen peroxide (3% for 5 min),
and residual avidin or biotin was quenched by sequential incuba-
tion in avidin (20 
 
m
 
g/ml for 20 min) or biotin (10 
 
m
 
g/ml for 20
min). Sections were then preincubated in 1.5 mM CoCl
 
2
 
 TdT
buffer (Boehringer Mannheim, Indianapolis, IN). Terminal deoxy-
nucleotide transferase (TdT, Boehringer Mannheim) was then
used to label nicked and fragmented DNA with biotin-conju-
gated dUTP at 37
 
8
 
C for 100 min (1.5 mmol CoCl
 
2
 
, 0.6 
 
m
 
l TDT,
1.5 
 
m
 
l biotin–dUTP per 100 
 
m
 
l buffer 
 
z
 
30 
 
m
 
l/4 cm
 
2
 
). Slides
were washed in 2
 
3
 
 SSC (15 min), incubated in 2% BSA (ELISA
grade, Sigma, St. Louis, MO) followed by Streptavidin–horserad-
ish peroxidase (Caltag, 1:1000, 30 min at 37
 
8
 
C). The slides were
developed with diaminobenzidine (DAB; Pierce, Rockford, IL)
for 2 min.
Immunohistochemistry for insulin was then performed using a
two-step protocol. Endogenous peroxidase activity was blocked,
and slides were incubated with rabbit antiserum to insulin (Dako
Corp., Carpenteria, CA; 1:500 in 5% normal mouse serum for 30
min). After wash steps, staining was revealed with horseradish
peroxidase–conjugated anti-rabbit Ig (Dako; 1:500 in 5% NMS
for 30 min), developed with aminoethylcarbazole (AEC; Pierce)
for 10 min and mounted in crystalmount.
Cryosections were allowed to equilibrate to room temperature
and rehydrated in PBS for 10 min. Endogenous peroxidase activ-
ity was blocked, and slides were incubated with antibodies against
V
 
b
 
4 TCR (KT4) and CD4, macrophage subpopulations (MAC-1,
MOMA-1, MOMA-2, ERMP-23; all gifts of Dr. P. Leenen, Eras-
mus University, Rotterdam, The Netherlands), dendritic cells
(NLDC-145; Harlan Sera Labs, Indianapolis, IN), natural killer cells
(DX5; a gift of Dr. L. Lainer, DNAX, Palo Alto, CA), mad-CAM
(MECA-367), and peripheral node addressin (MECA-79; both
mAb gifts from Dr. P.R. Streeter, Monsanto, St. Louis, MO) for
60 min at room temperature in a humidified container. After
wash steps, staining was revealed with horseradish peroxidase–conju-
gated goat anti–rat Ig (Caltag; 1:500 in 5% NMS for 30 min), de-
veloped with AEC for 10 min, and mounted in crystalmount. For
each pancreas, multiple parallel sections were analyzed in five lev-
els, each 0.5 mm apart, in order to minimize sample error.
 
T Cell Transfers.
 
Naive CD4
 
1
 
 T cells were enriched from
thymi of BDC2.5/NOD mice by depleting CD4
 
1
 
 CD8
 
1
 
 dou-
ble-positive cells with anti-CD8 antibody and rabbit complement
(Cederlane, Ontario, Canada). T cells were resuspended at 1 
 
3
 
10
 
5
 
 cells/ml in DMEM supplemented with 10% heat-inactivated
fetal bovine serum, 1 mM sodium pyruvate, 1 mM glutamine,
and 50 
 
m
 
M 2-mercaptoethanol and incubated with 2 
 
3
 
 10
 
6
 
APC/ml and 2 
 
3
 
 10
 
4
 
 islet cells in conditions previously demon-
strated to generate Th1 or Th2 cells for 7 d (12, 23). In brief,
T cells were cultured in the presence of islet cells and NOD sple-
nocytes in the presence of IFN-
 
g
 
 (50 U/ml) and IL-12 (50 U/ml),
and neutralizing anti–IL-4 antibodies (11B11, 10 
 
m
 
g/ml) for gen-
eration of Th1 T cells or IL-4 (50 U/ml) and neutralizing amounts
of anti IFN-
 
g
 
 (H22, 10 
 
m
 
g/ml) and anti IL-12 (Tosh, 10 
 
m
 
g/ml)
antibodies for Th2 T cells. T cells were recovered from these cul-
tures and transferred into neonatal NOD or 6-wk-old NOD.
 
scid
 
mice. An aliquot of cells was restimulated with antigen and APC
alone and supernatants were checked for the presence of appro-
priate cytokines by ELISA to confirm polarization of T cells.
Neonatal NOD mice were injected with 1 
 
3
 
 10
 
6
 
 CD4
 
1
 
 V
 
b
 
4
 
1
 
Th1 or Th2 T cells intraperitoneally, whereas NOD.
 
scid
 
 and
TCR-
 
ab
 
–deficient NOD (NOD.C
 
a
 
2
 
/
 
2
 
) mice were injected
with 1 
 
3
 
 10
 
6
 
 cells intravenously.
In mice treated with neutralizing cytokine antibodies, mice re-
ceived 250 
 
m
 
g of anti-IL-4 (11B11), or anti-IL-10 (2A5) 1 d be-
fore receiving Th2 cells and then every 3 d thereafter.
 
In Vitro Restimulation.
 
Th2 T cells stimulated as above were
recovered and cultured for an additional 7 d in the presence of
antigen under either Th2 conditions (anti–IL-12, anti-IFN-
 
g
 
,
and IL-4), Th1 conditions (anti–IL-4, IFN-
 
g
 
, and IL-12), or
Th1/Th2 conditions (IL-4, IL-12, and IFN-
 
g
 
) to evaluate Th2
phenotype stablity. At the end of the second 7-d cycle, recovered
T cells were restimulated with islet cells and irradiated NOD
APC in the absence of exogenous cytokines or mAb, and super-
natant were collected and analyzed by ELISA at 24 h. 
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Cytokine ELISA.
 
IL-4 was detected using monoclonal anti-
IL-4 antibody (11B11) as the capture antibody and revealed with
rabbit anti-mouse IL-4 polyclonal serum (a gift of Dr. R.D.
Schreiber, Washington University, St. Louis, MO) followed by
biotin-conjugated goat anti–rabbit antibody (Vector) and Strepta-
vidin–horseradish peroxidase (Jackson Immunoresearch, Avon-
dale, PA) using TMB substrate (Sigma). IFN-
 
g
 
 was detected us-
ing H22 (gift of Dr. R.D. Schreiber) as the capture antibody and
revealed with goat anti–mIFN-
 
g
 
 antibody followed by horserad-
ish peroxidase–conjugated donkey anti–goat IgG (Jackson Immu-
noresearch) using ABTS (Sigma) as substrate.
 
Results
 
Th2 Cells Transfer Disease in NOD.scid Mice.
 
We gener-
ated Th1 and Th2 cells from naive populations of BDC2.5/
NOD.
 
scid
 
 thymocytes by in vitro stimulation with islet cells
in the presence of anti-IL-4, recombinant IFN-
 
g
 
, and IL-12
for Th1, or anti–IL-12 and anti–IFN-
 
g
 
, and recombinant
IL-4 for Th2 cells. T cells taken from these cultures were
restimulated in the presence of islet cells and APC alone and
the supernatants were tested for the presence of appropriate
signature cytokines by ELISA confirming the polarization
of the T cells (data not shown). Th1- or Th2-polarized
BDC2.5 T cells were then injected into either neonatal
NOD (immune-competent) mice or NOD.
 
scid
 
 (immune-
compromised) mice, and the recipient animals were moni-
tored for diabetes by blood glucose. Th1-injected neonatal
NOD mice became diabetic by day 14, whereas Th2-injected
neonatal recipient mice remained normal glycemic even af-
ter 35 d (Fig. 1 
 
a
 
). Moreover, when Th1 T cells from the same
polarized cultures were transferred into 6-wk-old NOD.
 
scid
 
mice, diabetes was likewise rapidly induced (Fig. 1 
 
b
 
). The
rate, progression, and penetrance of disease was identical to
that seen in neonatal recipients of Th1 cells (Fig. 1, 
 
a
 
 and
 
b
 
), with sustained hyperglycemia appearing between day 9
and 14 after-transfer (Fig. 1 
 
b
 
). Insulitis, as determined from
serial pancreas histology, started at day 5 and becoming se-
vere by day 9 (data not shown). Moreover, when Th1 cells
were transferred into NOD mice lacking 
 
ab
 
–T cells
(NOD C
 
a
 
2
 
/
 
2
 
), hyperglycemia resulted with similar kinet-
ics and penetrance (data not shown). Therefore, Th1 cells
produced similar disease in both immune-compromised
and immune-competent mice. In addition, the Th1-medi-
ated disease was nearly identical to the diabetes seen with
BDC2.5/NOD.
 
scid
 
 T cells from spontaneously diabetic an-
imals (8).
Surprisingly, unlike the Th2 recipient neonatal NOD,
which remained disease free, immune-compromised NOD
mice (both NOD.
 
scid
 
 and NOD C
 
a
 
2
 
/
 
2
 
) infused with Th2
cells developed hyperglycemia (Fig. 1 
 
b
 
; data not shown).
However, the kinetics and penetrance of disease were dif-
ferent from that seen in Th1-mediated disease. Islet-reac-
tive Th2 cells produced disease with slower kinetics and
only partial penetrance in NOD.
 
scid
 
 recipients (Fig. 1 
 
b
 
).
By day 16, 25% of the mice were diabetic and maximum
disease penetrance was not achieved until day 24 with 60%
of the mice showing sustained hyperglycemia. This slow
disease seen in NOD.scid recipients of Th2 cells could be
due to (a) the slow expansion of a contaminating Th1 T cell
population or a switch of the input T cell population to Th1
or (b) a unique Th2 lesion with inherently slower kinetics.
We addressed the first possibility by taking polarized Th2
T cells and assessing their ability to switch phenotypes both
in vitro and in vivo. In culture, naive BDC2.5 T cells were
stimulated under conditions that generated Th2 T cells as
above. However, after one round of culture, Th2 T cells
were then subjected to a secondary antigenic stimulation in
the presence of IL-12 and IFN-g (Th1 condition) that fa-
vors the outgrowth of Th1 cells or the phenotypic switch of
poorly polarized Th2 T cells. The presence of IFN-g–pro-
ducing cells is then revealed under neutral reconditions. Even
after 1 wk of culture with IFN-g and IL-12, we were un-
able to detect IFN-g production by our Th2 cells (data not
shown). More directly, splenocytes recovered from NOD.scid
recipient mice were stimulated with plate-bound anti-CD3,
and the supernatants were assayed for both Th1 and Th2
cytokines. We found that the recovered splenocytes could
only secrete IL-4 in detectable quantities (data not shown).
From this, we concluded that Th2 cells did not switch
phenotype after polarization, nor did a contaminating Th1
population grow out from the input Th2 transfer popula-
tion.
Th2 T Cells Induce a Novel Pancreatic Lesion. The best evi-
dence supporting a unique Th2-mediated disease was radi-
cally different histopathology of the Th2 lesions in NOD.scid
mice. Th1 T cells and those from spontaneously diabetic
BDC2.5/NOD.scid mice produce focused islet lesions with-
out involvement of the surrounding exocrine tissue (Fig. 2
a; reference 8). That is to say, the infiltrating mass of leuco-
cytes surrounded the islets (peri-insulitis) and then pro-
ceeded to invade the islet from the periphery to the center
(insulitis). The infiltrating mass was predominantly Vb41,
CD41 T cells, macrophages with a few neutrophils (see be-
low). By contrast, Th2 T cells followed a more disorga-
nized pattern. Leucocytes infiltrated not only the islets but
Figure 1. Transfer of diabetes with both Th1- and Th2-like cells into
NOD.scid mice. (a) Th1 cells (closed circles) transfer diabetes into neonatal
NOD mice in 7–14 d, while Th2 cells (open circles) do not transfer even
up to 35 d. (b) Th1 and Th2 cells transfer diabetes into NOD.scid mice.
Diabetes was assessed by measuring blood glucose. Mice with two con-
secutive blood sugar readings above 250 mg/dl were considered diabetic.
Onset was dated to the first of the two consecutive readings.302 Autoimmune Diabetes by Th2 Cells
also the exocrine tissue (Fig. 2 b) with significant damage
produced to the exocrine tissue as well as islets (Fig. 2, b
and f). The Th2 lesions contained a swarming pancreatitis
predominantly composed of eosinophils and PMN cells
(Fig. 2 f). Additionally, the Th2 lesions were characterized
by the presence of abscesses as evidenced by the massive ac-
cumulation of eosinophils and PMNs with necrotic cellular
debris with in the islets (Fig. 2, b and f).
The organized outside–in pattern of Th1 T cell–medi-
ated infiltration was associated with b cell apoptosis. Insu-
lin-containing b cells were present in the intact areas of
infiltrated islets (Fig. 2 c), whereas infiltrated areas saw a loss
of insulin-bearing islet cells. Th1 lesions showed b cells apop-
tosis (Fig. 2 e) similar to that seen in spontaneous disease
(8). There was a strict correlation between the presence of
insulitis and and b cell apoptosis. Cell death in the Th2 cell
infiltrated islets by contrast was due largely to necrosis and
subsequent abscess formation (Fig. 2 e). It is worth noting
that the islet cell necrosis in Th2 lesions was often asym-
metric or segmental especially with large islets where one
portion of the islet would be completely necrotic and the
adjacent islet mass completely intact and producing insulin
(Fig. 2 d).
Dramatic differences in the organization and cellular
makeup of the two lesions was further underscored upon
immunohistochemical labeling of pancreatic frozen sections
from NOD.scid mice infused with Th1 and Th2 T cells.
Fig. 3 a depicts a section of a Th1 T cell–induced lesion,
showing an accumulation of transgenic Vb41 T cells pe-
ripheral to the infiltrated islet. The exocrine tissue was
largely devoid of any T cells. By contrast, in Th2 lesions,
abscess formation was seen with a few weakly staining
CD41, Vb41 T cells associated with both islet and the pe-
ripheral exocrine tissue (Fig. 3 b). In general, T cell staining
was weak and diffuse and made up only a small portion of
the total leukocytic infiltration within the inflamed pan-
Figure 2. Distinct lesions cre-
ated by Th1 and Th2 cells in
NOD.scid mice. Photomicro-
graphs of pancreatic tissue sec-
tions stained with hematoxylin
and eosin, (a) Th1, and (b) Th2.
Th1 lesion shows confined peri-
insulitis and insulitis pattern with
little exocrine inflammation and
damage, whereas Th2 lesion
shows swarming pancreatitis with
infiltration of the exocrine and
endocrine tissue. Arrow in b
indicates exocrine infiltration
and damage. Pancreatic sections
stained with anti-insulin (AEC)
counterstained with hematoxy-
lin reveals b cell function; Th1
(c) and Th2 (d). Th1 lesion
shows the outside–in pattern of
islet destruction with intact insu-
lin-producing  b cells in the
center of the islet, whereas Th2
lesion shows characteristic asym-
metric destruction of islet by ne-
crosis. Th1 lesion stained for
TUNEL1 nuclei (DAB) and
counterstained with hematoxylin
and eosin (e). Arrows indicate
apoptotic b cells. Hematoxylin
and eosin staining of a Th2 le-
sion shows a necrotic islet mass
containing eosinophils (arrows)
and other PMN and cell debris
(f). Original magnifications: a
and  b, 503; c–f, 1003.303 Pakala et al.
creas. Macrophage subpopulations were present in both
Th1 and Th2 lesion as ascertained by CD11b, MOMA-1,
MOMA-2, and ER-MP23 staining (data not shown).
However, the Th2 lesions had a larger number of scaven-
ger macrophages surrounding the islet abscesses.
Peripheral Node Addressin Is Not Expressed in the High En-
dothelial Venules of Th2 Recipient Mice. Both Th1 and Th2
lesions showed mad-CAM on the high endothelial venules
with in the pancreas (Fig. 3, c–d). However, Th2 lesions
lacked expression of the activated form, peripheral node
addressin, PNA, as detected by the MECA-79 mAb (Fig. 3,
e–f). This was significant because PNA expression requires
localized production of IFN-g and TNF-a, again suggest-
ing that Th2 lesions lack significant production of these
Th1 cytokines.
IL-10 Antibody Treatment Protects NOD.scid Mice from
Th2-mediated Diabetes. To rule out the contribution of
neutrophils and granulocytes in the pancreatitis associated
with Th2 T cell transfer, we treated mice with a granulo-
cyte-specific mAb RB6 at concentrations sufficient to se-
verely deplete granulocytes in vivo (24, 25). We found no
change in disease or in the characteristics of the Th2 lesion
when granulocytes and neutrophils were depleted from
mice injected with Th2 cells (data not shown). However,
when we treated Th2 recipient NOD.scid mice with neu-
tralizing antibodies against IL-10, a Th2 cytokine previously
shown to have a major effect on autoimmune diabetes, the
Th2-mediated disease was significantly ameliorated. This
was not true for another Th2 cytokine, IL-4 (Fig. 4).
NOD.scid mice received either 250 mg of anti–IL-4, anti–
IL-10, or saline every 72 h, with the first dose 24 h before
infusion of the Th2 T cells. As depicted in Fig. 4, anti–IL-4
treatment did not protect from diabetes, whereas anti–IL-10
significantly delayed or abrogated the Th2 pathology. His-
tology performed on pancreas from these mice indicate no
change in the lesion characteristics, yet anti–IL-10 treat-
Figure 3. Immunohistochem-
istry on pancreatic sections from
NOD.scid mice transferred with
Th1 or Th2 cell. Th1 T cell le-
sion stained for anti-Vb4 shows
organized transgenic T cell infil-
tration surrounding islet (a). Th2
lesion stained for anti-Vb4 shows
scattered T cell localization and
central necrotic mass with cell
debris (b). MECA-367 mAb stain-
ing to reveal mad-CAM expres-
sion on high endothelial venule
in both Th1 (c) and Th2 (d), le-
sions. MECA-79 mAb staining
to reveal peripheral node ad-
dressin on HEV. PNA staining is
present on HEV from Th1 lesion
(e), but lacking on HEV from
Th2 lesion (f). All photomicro-
graph original magnifications:
403. Staining revealed by AEC
and counterstained in hematox-
ylin.304 Autoimmune Diabetes by Th2 Cells
ment substantially protected against Th2 lesions, suggesting
that IL-10 contributes to the pathology of Th2 disease.
Discussion
We reported that Th2 cells were capable of inducing hy-
perglycemia in immune-compromised NOD.scid mice but
not in neonatal NOD mice. The kinetics of disease was
slower when compared with Th1-mediated disease due to
a different mechanism of islet cell destruction. The Th2 le-
sions were characterized by a predominantly eosinophilic
infiltration, islet necrosis and abscess, and a severe pancre-
atitis with destruction of both exo- and endocrine tissue.
By contrast, Th1 T cells produced focally confined infiltra-
tion of the islets and b cell apoptosis which largely spares
the adjacent exocrine tissue. This was more reminiscent of
the lesions seen in the natural disease and in our spontane-
ous TCR transgenic model of disease (8, 12).
Two important question arise from these findings. First,
how do Th2 T cells propagate the pancreatitis and necrosis
of islet cells in the immune-compromised recipient? And,
second, why is the Th2 lesion found exclusively in im-
mune-compromised hosts? Addressing the former, our data
suggest that a particularly important mediator of islet cell
necrosis is IL-10. Interestingly, previously published reports
using transgenic mice that produced IL-4 in the islets were
protected from diabetes, whereas local production of IL-10
produced a severe disease (26–28). These observations agree
well with our findings that anti–IL-10 treatment of Th2
T cell recipients greatly diminishes disease onset and con-
current pathology. Wogensen et al. (26) have suggested that
localized production of IL-10 produces important changes
in the vascular endothelium, which may lead to accumula-
tion of T cells, macrophage and eosinophils by changing
the vascular addressin expressed on the endothelium. How-
ever, if the local production of IL-10 by our Th2 T cells
acted predominantly to stimulate homing, treatment of the
recipients with anti–IL-10 should have diminished greatly
the eosinophilic nature of infiltration. However, we found
that anti–IL-10 had a far greater effect on the pathology of
the lesion than on its cellularity. One hypothesis is that
IL-10 leads to vascular damage resulting in hypoxia and
subsequent abscess formation. Moritani et al. (28) have previ-
ously described ductal proliferation as an effect mediated by
transgenic expression of IL-10. Alternatively, owing to the
venation of microcapillaries that feed islets (29), localized
endothelial damage produced by IL-10 could lead to vascu-
lar occlusion of one of the branches feeding the microvas-
cular circulation of the islet, resulting in the segmented necro-
sis that affected many of the larger islets. However, we have
not found any direct evidence to support this interpretation.
The susceptibility of immune-compromised animals to
Th2-mediated disease may lie with the activated state of
the innate immune system in the absence of specific immu-
nity. Specifically, IL-10 secretion has pronounced effects
on mononuclear phagocyte development and can enhance
the development of the myelomonocytic lineage (30–32).
However, the most likely explanation rests with the lack of
additional ab–T cells. It is likely that Th2 cell regulation
requires interactions with other ab–T cells. Because in
both our results and those of Lafaille et al. (33), the exag-
gerated and deleterious Th2 phenotype occurs only in the
absence of diverse ab–T cell compartment, how the pres-
ence of other T cells affect the in vivo function of Th2 re-
mains to be seen.
It would be of obvious clinical advantage if one could
deviate an ongoing inflammatory immune response to a
benign Th2 response. Some have even suggested that Th2
T cells are suppressive or tolerant T cells, reviewed and dis-
cussed in references 11, 34. But it is clear that some doubts
have existed as to the efficacious use of Th2 therapy to treat
inflammatory-based diseases (35–37). Our results demon-
strate that Th2 cells may not be all that benign, especially if
pushed to extremes, and carry with them a real potential to
cause clinical disease. This is of particular concern in the
case at hand, autoimmune diabetes, where immune devia-
tion therapy as proposed in conjunction with islet cell trans-
plantation and immunosuppression may cause a severe ne-
crotic destruction of engrafted islets. Moreover, this may
not be a limited phenomenon as similar studies in experi-
mental autoimmune encephalomyelitis yield remarkably
similar results (33).
Figure 4. Anti–IL-10 mAb treatment protects NOD.scid mice from
Th2-mediated disease. Mice were treated with 250 mg of purified mAb
against IL-10 (2A5) and IL-4 (11B11) every 72 h. Open circles represent
anti–IL-10–treated mice and closed circles represent anti–IL-4–treated
mice. Diabetes was assessed by measuring blood glucose. Mice with two
consecutive blood sugar readings above 250 mg/dl were considered dia-
betic. Onset was dated to the first of the two consecutive readings.
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